Natalizumab

Table   Graphic     exposition period:

Congenital malformations
Adverse outcome VerdictOR 95%CII2k No. casesNo. exposedpublication biasROB???
All congenital malformations (majors, minors, majors and minors, or unspecified)5.51 [1.10, 27.66]-1 study954not evaluable NA
2 non statistically significant endpoints reported in only one study

Growth parameters and prematurity
Adverse outcome VerdictOR 95%CII2k No. casesNo. exposedpublication biasROB???
Preterm (< 37 weeks)0.84 [0.46, 1.52]31%2 studies235111not evaluable NA
Low birth weight (< 2500g)--0 study

Maternal consequences
Adverse outcome VerdictOR 95%CII2k No. casesNo. exposedpublication biasROB???
Caesarean--0 study
Maternal consequences (as a whole)3.50 [1.02, 12.05]-1 study1354not evaluable NA

Intrauterine deaths
Adverse outcome VerdictOR 95%CII2k No. casesNo. exposedpublication biasROB???
Elective termination of pregnancy2.26 [0.33, 15.52]82%2 studies48147not evaluable NA
4 non statistically significant endpoints reported in only one study

Neuro-developmental disorders
Adverse outcome VerdictOR 95%CII2k No. casesNo. exposedpublication biasROB???
1 non statistically significant endpoints reported in only one study